Search

Displaying results 51 - 60 of 48101 in total
  1. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    [A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal … However, it has a negligible effect on altering the development and progression of breast cancer itself.

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 InhibitorsSynonyms: (2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone
  2. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    [A246693] Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein that is overexpressed in malignant cells and is upregulated by oncogenes. … Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts.

    Categories: Heterocyclic Compounds, 2-RingSynonyms: (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid, N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid
  3. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
  4. Drug

    Clarithromycin

    go.drugbank.com/drugs/DB01211
    ApprovedInvestigational

    Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.

    Mixtures: HELIPAK 500 + 30 + 1000mg TEDAVİ PAKETİ, 7 TABLET, TRIO 1000 MG + 500 MG + 30 MG TEDAVİ PAKETİ, 6X7 ADETCategories: P-glycoprotein inhibitors, P-glycoprotein substrates
  5. Drug

    Chlorothymol

    go.drugbank.com/drugs/DB19375
    Approved

    Chlorotymol is a [Thymol] derivative.

    Synonyms: 6-chlorothymol, 4-chlor-2-isopropyl-5-methylphenol
  6. Drug

    4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide

    go.drugbank.com/drugs/DB03307
    Experimental

    Synonyms: 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  7. Drug

    Moxifloxacin

    go.drugbank.com/drugs/DB00218
    ApprovedInvestigational

    Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. … Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

    Synonyms: 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acidMixtures: Ixoba M, TQ OFTAMOX D UD®
  8. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

    Categories: 4-Quinolones, Heterocyclic Compounds, 2-RingSynonyms: 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid, 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
  9. Drug

    Zolpidem

    go.drugbank.com/drugs/DB00425
    ApprovedInvestigational

    Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury. … Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia.

    Mixtures: Gabazolpidem-5, Sentrazolpidem PM-5Categories: GABA-A Receptor Agonists, Cytochrome P-450 Substrates
  10. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide